Industry Exploration: Hemostats Market Growth, Business Scope, Key Drivers, and Forecast Spanning Through 2028

In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.


Northbrook, IL 60062 -- (SBWIRE) -- 12/05/2023 -- Hemostats Market in terms of revenue was estimated to be worth $2.7 Billion in 2023 and is poised to reach $3.7 Billion by 2028, growing at a CAGR of 6.7% from 2023 to 2028 according to a new report by MarketsandMarkets.
The hemostats industry is poised for significant growth in the near future, driven by a confluence of factors including the rising prevalence of surgical procedures, increasing trauma cases, and advancements in medical technology. With a growing aging population and a higher demand for minimally invasive surgeries, the need for effective hemostatic agents and devices will continue to expand. Additionally, the development of innovative hemostatic products with improved safety profiles and quicker clotting times will further bolster the industry's prospects. As healthcare systems worldwide focus on enhancing patient outcomes and reducing healthcare costs, the hemostats industry is expected to play a pivotal role in achieving these goals, making it a vital and thriving sector in the coming years.

The significant growth in the number of hospitals and surgical centers is expected to support the growth of the hemostats market, as these are key end users of hemostats. The number of hospitals and surgical centers is increasing in both developed and emerging countries. The demand for surgical equipment (including medical devices such as hemostats) is high in these newly established surgical centers and hospitals, owing to the increasing patient population base.

Download an Illustrative overview:

Browse in-depth TOC on "Hemostats Market"

186 - Tables
43 - Figures
222 - Pages

In 2022, the oxidized regenerated cellulose-based hemostats segment held the largest share of the hemostats market by type segment.

The hemostats market is segmented into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats based on type. The oxidized regenerated cellulose-based hemostats segment accounted for the largest share of the hemostats market in 2022. These hemostatic agents have emerged as frontrunners in the hemostats market. ORC-based hemostatic agents have showcased their effectiveness across a broad spectrum of surgical procedures. Whether in general surgery, cardiovascular surgery, orthopedics, or other specialties, ORC-based options have consistently demonstrated their hemostatic capabilities. This versatility has made them an attractive choice for surgeons who encounter diverse clinical scenarios.

The matrix & gel hemostats segment held the largest share of the hemostats market by formulation segment in 2022.

The global hemostats market is differentiated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2022, the matrix & gel hemostats segment dominated the hemostats market. These formulations strike a balance between versatility and effectiveness, appealing to a broad spectrum of surgical scenarios.

North America is the largest regional market for hemostats market.

The market for hemostats has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the predominant portion of the hemostats market. The hemostats market in North America is well-established, with the US being a major market in this region. Growth in the North American market is mainly driven by the growing geriatric population and the increasing number of surgeries performed in the region. The rising prevalence of chronic diseases is expected to increase the number of surgical procedures performed, thereby increasing the demand for hemostats.

Request Sample Pages:

Hemostats Market Dynamics:


1. Growing volume of surgical procedures performed
2. Rising focus on R&D
3. Rising focus on effective blood loss management in patients during surgeries


1. Side effects and allergic reactions associated with hemostats


1. Growth opportunities in emerging economies
2. Growing number of hospitals


1. Stringent regulatory framework
2. Dearth of skilled personnel for effective use of hemostats
3. High cost of hemostats

Key Market Players of Hemostats Industry:

The major players operating in this market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey).

Recent Developments:

- In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.
- In July 2023, Baxter International (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients.
- In December 2020, Teleflex (US) acquired Z-Medica, LLC (US), a medical device company that manufactures and sells hemostatic (hemorrhage control) products.
- In March 2020, Ethicon announced the strategic regional launch of the SURGICEL Powder Absorbable Hemostat in Australia, New Zealand, and Thailand.
- In December 2019, Advanced Medical Solutions Group (UK) acquired Biomatlante (France), a well-established international developer and manufacturer of innovative surgical biomaterial technologies.

Get 10% Free Customization on this Report:

Hemostats Market Advantages:

- Enhanced Patient Safety: Hemostats provide a reliable means to control bleeding during surgical procedures, reducing the risk of excessive blood loss, which can lead to complications and post-operative issues.
- Minimally Invasive Options: Many modern hemostatic products are designed for minimally invasive surgeries, allowing for smaller incisions, reduced scarring, and faster patient recovery.
- Improved Surgical Efficiency: Hemostatic agents help surgeons work more efficiently by minimizing bleeding, enabling them to focus on the surgical task at hand, which can lead to shorter operation times.
- Wider Applicability: Hemostats are used in various medical specialties, including general surgery, cardiovascular surgery, orthopedics, and gynecology, making them versatile tools in the medical field.
- Reduced Blood Transfusions: Effective hemostats can decrease the need for blood transfusions, which not only saves costs but also lowers the risks associated with transfusion-related complications.
- Cost-Efficiency: By reducing the likelihood of complications, extended hospital stays, and the need for additional interventions, hemostatic agents contribute to cost savings in the healthcare system.
- Research and Innovation: The hemostats market continues to see significant research and development, resulting in the creation of advanced hemostatic products with improved safety profiles and performance.
- Trauma Care: Hemostats play a crucial role in trauma care, allowing for rapid bleeding control in emergency situations, which can be life-saving.
- Global Demand: The increasing number of surgeries and trauma cases worldwide ensures a consistent demand for hemostats, making it a stable and growing market.
- Healthcare Advancements: As medical technology and surgical techniques evolve, hemostats will continue to adapt and integrate with these advancements, contributing to better patient outcomes and the overall advancement of healthcare.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441